Disclosures: Prajna Anirvan: Nothing to Disclose, Zaiba Khan: Nothing to Disclose, Pallavi Bhuyan: Nothing to Disclose, Sujata Dixit: Nothing to Disclose, Rishikesh Dash: Nothing to Disclose, Priyanka Mishra: Nothing to Disclose, Giriprasad Venugopal: Nothing to Disclose, Gowri Balachander: Nothing to Disclose, Pankaj Bharali: Nothing to Disclose, Mrinal Gogoi: Nothing to Disclose, Chitta Ranjan Khatua: Nothing to Disclose, Manas Panigrahi: Nothing to Disclose, Manoranjan Ranjit: Nothing to Disclose, Balamurugan Ramadass: Nothing to Disclose, Shivaram Singh: Boehringer Ingelheim International GmbH: Advisor, Sun Pharma: Stock - publicly traded company, Torrent Pharmaceuticals: Stock - publicly traded company, Dr Reddy's Labs: Stock - publicly traded company, Panacea Biotech Ltd: Stock - publicly traded company 606 BIOMARKER RESPONSE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) PATIENTS WITH HIGH-RISK BASELINE FAST SCORES: OBSERVATIONS FROM THE ENLIVEN PHASE2B TRIAL WITH PEGOZAFERMIN Cynthia Hartsfield 1 Naim Alkhouri 2 Quentin Anstee 3 Rohit Loomba 4 Manal Abdelmalek 5 Kris Kowdley 6 Maya Margalit 1 Mildred Gottwald 1 Germaine Agollah 1 Shibao Feng 1 Hank Mansbach 1 Arun Sanyal 7 , 1 89bio, 2 Arizona Liver Health, 3 Newcastle University, UK, 4 University of California, San Diego, 5 Mayo Clinic Rochester, 6 Liver Institute Northwest, 7 Virginia Commonwealth University Background: ENLIVEN was a 48-week study of the FGF21 analog, pegozafermin (PGZ), in subjects with biopsy-proven F2/F3 MASH

Feng J-J, Huang H, Zhou D-L et al (2013) Peptide-templated synthesis of wavelength-tunable fluorescent gold nanoparticles
The major role of glucocorticoid receptor (GR) in astaxanthin alleviates immune stress in Channa argus lymphocyte
Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
25 However, most of the subsequent studies focused on the functions of the gut microbiome, fecal microbiome, etc., in the lung